AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Currently Amended) A method for reducing PGE2 mediated inflammation, comprising administering a composition comprising a reduced isoalpha acid (RIAA) selected from dihydro-isohumulone, dihydro-isocohumulone, and dihydro-isoadhumulone ~~is of chemical structure:~~



and an isoalpha acid (IAA) selected from isohumulone, isocohumulone, and isoadhumulone ~~of chemical structure:~~



~~wherein R" is selected from the group consisting of $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, and~~

~~$CH(CH_3)CH_2CH_3$~~, wherein the RIAA and IAA are in synergistic amounts in a therapeutically effective anti-inflammatory ratio of about 3:1 to about 1: 10 and wherein said RIAA and IAA individually comprise at least 0.1% of the composition.

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Previously Presented) The method of claim 4, wherein the reduced isoalpha acid (RIAA) and isoalpha acid (IAA) are derived from hops.

10. (New) The method of claim 4, wherein the composition comprises from about 50 mg to about 7500 mg of the reduced isoalpha acid.

11. (New) The method of claim 4, wherein the composition comprises from about 50 mg to about 7500 mg of the isoalpha acid.

12. (New) The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable carrier.

13. (New) The method of claim 4, wherein the composition is administered orally, topically, parenterally, or rectally.